The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Camilla Friis Bryde Nielsen, Sanne Møller Thysen, Freja Bach Kampmann, Tine Willum Hansen, Niklas Rye Jørgensen, Nete Tofte, Signe Abitz Winther, Simone Theilade, Peter Rossing, Marie Frimodt-Møller, Allan Linneberg
{"title":"The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.","authors":"Camilla Friis Bryde Nielsen, Sanne Møller Thysen, Freja Bach Kampmann, Tine Willum Hansen, Niklas Rye Jørgensen, Nete Tofte, Signe Abitz Winther, Simone Theilade, Peter Rossing, Marie Frimodt-Møller, Allan Linneberg","doi":"10.1111/dom.16025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Vitamin K deficiency is common in persons with kidney disease, which is a known complication of diabetes. We aimed to assess the association of vitamin K status as reflected by plasma dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) with mortality, cardiovascular disease (CVD) and progression to end-stage kidney disease (ESKD) in persons with type 1 diabetes.</p><p><strong>Materials and methods: </strong>We analysed plasma dp-ucMGP in stored baseline samples from a cohort of 667 persons with type 1 diabetes (baseline visit: 2009-2011). Information on mortality and CVD was obtained through linkage to registers. Cox-proportional hazards models were applied to estimate hazard ratios (HRs) of mortality, CVD and ESKD per one doubling of dp-ucMGP.</p><p><strong>Results: </strong>A total of 53 deaths were recorded during follow-up. Persons with higher dp-ucMGP (reflecting lower vitamin K status) had higher mortality in the unadjusted model (HR: 2.06 [95% confidence interval-CI: 1.22-3.45]), but not in the fully adjusted model (HR: 0.88 [95% CI: 0.44-1.73]). Particularly, adjustment for glomerular filtration rate and urinary albumin excretion rate attenuated the HR. A similar pattern was observed in unadjusted models for incidence of CVD (HR: 1.58 [95% CI: 1.03-2.42]) and risk of ESKD (HR: 7.62 [95% CI: 4.25-13.68]). In the fully adjusted models, the HRs became statistically insignificant.</p><p><strong>Conclusion: </strong>In persons with type 1 diabetes, lower vitamin K status was associated with higher mortality, CVD and progression to ESKD, however, not after adjustment for other risk factors. Interventional studies are needed to elucidate the role of vitamin K in persons with type 1 diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16025","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Vitamin K deficiency is common in persons with kidney disease, which is a known complication of diabetes. We aimed to assess the association of vitamin K status as reflected by plasma dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) with mortality, cardiovascular disease (CVD) and progression to end-stage kidney disease (ESKD) in persons with type 1 diabetes.

Materials and methods: We analysed plasma dp-ucMGP in stored baseline samples from a cohort of 667 persons with type 1 diabetes (baseline visit: 2009-2011). Information on mortality and CVD was obtained through linkage to registers. Cox-proportional hazards models were applied to estimate hazard ratios (HRs) of mortality, CVD and ESKD per one doubling of dp-ucMGP.

Results: A total of 53 deaths were recorded during follow-up. Persons with higher dp-ucMGP (reflecting lower vitamin K status) had higher mortality in the unadjusted model (HR: 2.06 [95% confidence interval-CI: 1.22-3.45]), but not in the fully adjusted model (HR: 0.88 [95% CI: 0.44-1.73]). Particularly, adjustment for glomerular filtration rate and urinary albumin excretion rate attenuated the HR. A similar pattern was observed in unadjusted models for incidence of CVD (HR: 1.58 [95% CI: 1.03-2.42]) and risk of ESKD (HR: 7.62 [95% CI: 4.25-13.68]). In the fully adjusted models, the HRs became statistically insignificant.

Conclusion: In persons with type 1 diabetes, lower vitamin K status was associated with higher mortality, CVD and progression to ESKD, however, not after adjustment for other risk factors. Interventional studies are needed to elucidate the role of vitamin K in persons with type 1 diabetes.

功能性维生素 K 状态与 1 型糖尿病患者的全因死亡率、心血管疾病和终末期肾病之间的关系。
背景和目的:维生素 K 缺乏症在肾病患者中很常见,而肾病是已知的糖尿病并发症之一。我们旨在评估血浆去磷酸化-非羧化基质Gla蛋白(dp-ucMGP)所反映的维生素K状态与1型糖尿病患者死亡率、心血管疾病(CVD)和终末期肾病(ESKD)进展的关系:我们分析了667名1型糖尿病患者队列中储存的基线样本中的血浆dp-ucMGP(基线访问:2009-2011年)。有关死亡率和心血管疾病的信息是通过与登记簿建立联系获得的。采用 Cox 比例危险模型估算了 dp-ucMGP 每增加一倍所导致的死亡率、心血管疾病和 ESKD 的危险比 (HRs):随访期间共记录了 53 例死亡。在未经调整的模型中,dp-ucMGP越高(反映维生素K状态越低)的人死亡率越高(HR:2.06 [95%置信区间:1.22-3.45]),但在完全调整的模型中(HR:0.88 [95% CI:0.44-1.73]),死亡率并不高。特别是对肾小球滤过率和尿白蛋白排泄率进行调整后,HR 值有所降低。在心血管疾病发病率(HR:1.58 [95% CI:1.03-2.42])和ESKD风险(HR:7.62 [95% CI:4.25-13.68])的未调整模型中也观察到类似的模式。在完全调整模型中,HRs 在统计学上变得不显著:结论:在 1 型糖尿病患者中,较低的维生素 K 状态与较高的死亡率、心血管疾病和 ESKD 的进展相关,但在调整其他风险因素后并非如此。需要进行干预性研究,以阐明维生素 K 在 1 型糖尿病患者中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信